Enteral NutritionADHENUTENCT07571564
Adherence to Enteral Nutrition
An observational study of Enteral Nutrition, run by Institut Curie at 1 site in France.
Trial summary
Malnutrition is a major challenge in cancer nutrition, affecting approximately 40% of cancer patients and having negative consequences on treatment efficacy, quality of life, and prognosis. It must be detected and managed early, based on clinical and laboratory criteria defined by the HAS recommendations. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Enteral Nutrition
- How many people
- 80 participants
- Where
- 1 siteFrance
- Study dates
- 5 Mar 2026to 4 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: We propose to conduct a prospective, single-center cohort study involving 80 patients. Patients will be enrolled at the Institut Curie in Saint Cloud over a 12-month period and followed for 6 months. Patients must be adults and hospitalized in a medical oncology ward.
Who may be able to join
- Patients hospitalized (including those in the day hospital) in a medical oncology unit;
- Adults;
- Men or women;
- Patients for whom enteral nutrition is indicated according to SFNCM recommendations;
Who cannot join
- Minors (under 18 years of age)
- Patients receiving end-of-life palliative care
- Individuals deprived of their liberty or under legal guardianship (including conservatorship);
- Adults under judicial protection;
- Inability to participate in the study for geographical, social, or psychological reasons.
- Persons referred to in Articles L. 1121-5 through L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g., minors, adults under guardianship, etc.).
- Patients who do not speak or understand French.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Institut Curie
Paris, 75248
Betty PEIGNELIN, betty.peignelin@curie.fr
About this study
Malnutrition is a major challenge in cancer nutrition, affecting approximately 40% of cancer patients and having negative consequences on treatment efficacy, quality of life, and prognosis. It must be detected and managed early, based on clinical and laboratory criteria defined by the HAS recommendations.
To address this, several nutritional strategies are available, ranging from fortified oral feeding to artificial nutrition. Enteral nutrition, which is more physiological and carries fewer risks than parenteral nutrition, is recommended as the first-line treatment. Tools such as personalized care plans and guidelines help tailor patient care.
Read more
However, enteral nutrition remains underutilized in clinical practice, despite the recommendations. The ADHENUTE study, conducted at the Institut Curie, showed low compliance with recommendations (31%) and a tendency to favor oral nutritional supplements, even in severely malnourished patients. The lack of traceability of decisions makes it difficult to identify barriers, although patient refusal is sometimes mentioned.
To improve this situation, corrective measures have been implemented:
- for patients, through educational workshops to help them better understand and accept enteral nutrition;
- for healthcare providers, through training sessions to address reservations and enhance knowledge.
A third phase of the study aims to evaluate the impact of these actions, with the goal of increasing adherence to recommendations and the use of enteral nutrition.
Read the detailed description
The primary goal in cancer nutrition is to prevent, limit, and treat malnutrition. On average, 40% of cancer patients are malnourished (with this prevalence rising to as high as 90% depending on the cancer's location and the stage of the disease). Studies have shown that malnutrition reduces the effectiveness of cancer treatments, patients' quality of life, and their prognosis for recovery.
Screening for and management of malnutrition must be initiated early and based on the recommendations of the French National Authority for Health (HAS) in its guidelines titled "Diagnosis of Malnutrition in Children and Adults," updated in November 2020 and November 2021. In adults, the diagnosis of malnutrition (and its severity) is based on phenotypic and etiological criteria, including weight loss, Body Mass Index (BMI), albumin levels, and muscle strength measurements.
Dietary measures and interventions-ranging from optimizing oral intake to the use of Oral Nutritional Supplements (ONS) and Artificial Nutrition (AN)-help combat malnutrition. Enteral nutrition, which utilizes the digestive system, is the more physiological and effective solution, carrying a lower risk of infection. It is the preferred first-line treatment over parenteral nutrition.
Healthcare professionals can use the HAS's Personalized Care Plans (PPS) for oncology, which propose strategies based on treatment, age, and tumor location, as well as the phase of treatment (curative, initial palliative, advanced, or terminal). The nutritional care decision tree, which establishes a management strategy based on the patient's nutritional status and the severity of malnutrition-and is not specific to oncology-is a validated tool.
Despite the recommendations, the use of enteral nutrition remains insufficient. Indeed, and more broadly, this issue of non-compliance with recommendations for the implementation of enteral nutrition is commonly observed. This is confirmed by the study conducted by Defteros et al., which demonstrated that adhering to ESPEN (European Society for Clinical Nutrition and Metabolism) recommendations in clinical practice is difficult.
At the Institut Curie, until now, there has been little data on the extent to which recommendations for initiating enteral nutrition are followed.
We designed the ADHENUTE study (ADHEsion to Enteral Nutrition) to assess adherence to an enteral nutrition program in medical oncology and compliance with recommendations for implementing this nutritional support, both before and after corrective measures were implemented.
The study is designed in three phases:
> Phase 1: Verification of the hypothesis that enteral nutrition is under-used compared to recommendations, through a retrospective analysis of 200 medical records, and identification of barriers to the implementation of this nutritional support.
This phase was completed and highlighted in an article submitted to the *Bulletin du cancer* in March 2025, titled "Underutilization of enteral nutrition in medical oncology compared to recommendations." This initial phase revealed a compliance rate of 31% with the recommendations for enteral nutrition [95% CI: 20-42]. It also provided insight into which nutritional products were most frequently prescribed. A comparison between the recommended theoretical nutritional management and the management actually implemented in practice reveals a shift away from "enteral nutrition" toward "oral nutritional supplements." Furthermore, among the 189 usable records, 45% of patients were severely malnourished. Patients who received enteral nutrition generally had a poorer nutritional status than the overall study population: 21 out of 22 patients were malnourished (15 severely). However, the more severe the malnutrition, the more resistant it becomes to treatment, rendering dietary measures ineffective [10] and increasing the risk of complications during their implementation (notably an increased risk of inappropriate refeeding syndrome).
In their 2015 article [11], Coti-Bertrand et al. recommend tracking the indication for enteral nutrition as part of their criteria for evaluating and improving practices: "The indication for enteral nutrition is specified in the medical record." In the Adhénute study, documentation did not allow for the identification of the reason for non-compliance with enteral nutrition recommendations in each case. Among the records analyzed, the patient's refusal of enteral nutrition was mentioned in 5 records. For the 50 cases where enteral nutrition was not initiated despite recommendations to do so, this lack of traceability makes it impossible to determine why enteral nutrition was not provided.
- Step 2: Implementation of corrective measures for patients requiring enteral nutrition through an educational presentation of the project, and for healthcare providers and prescribing physicians through training sessions.
The proposal for corrective measures constitutes the second phase of the Adhénute project. These measures were implemented exclusively at the Saint Cloud site. The Paris site benefited from standard practices for improving clinical care.
They targeted two groups:
> Patients for whom enteral nutrition is indicated: The full report on best practices for dietary management in oncology regarding enteral nutrition [12] states that it is recommended to obtain the patient's consent through informed consent.
As part of Adhénute's corrective measures, enteral nutrition programs were presented to patients through educational initiatives such as Patient Therapeutic Education (PTE) workshops, with the aim of improving their understanding of this approach, reducing their level of apprehension, and increasing adherence to this nutritional method. This workshop, titled "I'm Committed to Enteral Nutrition," was designed for individual sessions or to include a caregiver and was offered to patients requiring enteral nutrition-whether in outpatient care or hospitalized-as soon as the need was identified (often on the same day, making it difficult to formalize the workshop into a full-fledged PTE program with a comprehensive pathway including BEPs). It includes 6 tools that can be adapted to the patient (material and nasogastric tube cards / keyword cards / food intake pie chart / choice method cards / arrows to associate with adverse effects / question-and-answer bubbles). The "emotions wheel" is used at the beginning and end of the workshop. An informational brochure is provided at the end of the workshop.
> Healthcare providers (doctors, nurses, nursing assistants). Training sessions were offered to medical and nursing staff.
The results of the first phase of Adhénute were presented to prescribing physicians, along with a review of the recommendations for implementing enteral nutrition during medical staff meetings in the target departments.
A training session titled "Overcoming Reluctance Toward Enteral Nutrition" was offered to medical and nursing teams in the target departments. Designed as a participatory and interactive ETP workshop, this training helped identify common barriers conveyed to patients by healthcare staff, enhance knowledge about this approach, and clarify the expected benefits for the patient.
This step has been completed
> Step 3: Evaluation of the impact of the improvement measures implemented in Step 2 To this end, a prospective analysis of patient records from those hospitalized in a medical oncology unit following the implementation of improvement measures will be conducted at the Saint-Cloud site. We expect to see an increase in the rate of compliance with recommendations as a result of these improvement measures.
- Conditions
- Enteral Nutrition
- Keywords
- enteral nutrition, adherence to enteral nutrition, compliance with enteral nutrition guidelines, malnutrition, nutritional supplements, patient education workshops, training for healthcare staff
- Medical subject headings
- Malnutrition
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess compliance with recommendations for the implementation of enteral nutrition following the improvement measures implemented in Phase 2.
Percentage of patients for whom the recommendations are followed. Compliance with the recommendations will be assessed by comparing the recommended nutritional interventions with those actually implemented.
Measured: From enrollment to the end of follow-up, which is 6 months
Secondary outcomes (10)
Assess the traceability of the reasons for not following a recommendation to initiate enteral nutrition in the patient's medical record
Percentage of cases detailing the reasons for exclusion from the nutrition program
Measured: From enrollment to the end of follow-up, which is 6 months
Assess the role of the dietetics department in screening for malnutrition and in the implementation of enteral nutrition
Percentage of patients treated by the dietetics department
Measured: From enrollment to the end of follow-up, which is 6 months
Assess the delay in initiating enteral nutrition
Percentage of weight loss (since the onset of the disease) among patients at the start of enteral nutrition
Measured: Since the onset of the disease at the start of enteral nutrition
Evaluate the implementation of recommendations based on tumor location
Percentage of patients for whom the recommendations are followed, by cancer site
Measured: From enrollment to the end of follow-up, which is 6 months
Identify other nutritional support methods used as alternatives to enteral nutrition.
Percentage of patients who received: Dietary Counseling / Oral Nutritional Supplements / Parenteral Nutrition / none, instead of Enteral Nutrition.
Measured: From enrollment to the end of follow-up, which is 6 months
Assess the time required for the patient to tolerate enteral nutrition
Number of days between the first submission and acceptance
Measured: From enrollment to the end of follow-up, which is 6 months
Assess the duration of compliance
Number of days on enteral nutrition
Measured: From enrollment to the end of follow-up, which is 6 months
Describe the reasons for discontinuing enteral nutrition
number and reasons for withdrawals
Measured: From enrollment to the end of follow-up, which is 6 months
Assessing the resolution of malnutrition through the implementation of recommendations
Comparison of weight changes between patients receiving enteral nutrition and those not receiving enteral nutrition
Measured: From enrollment to the end of follow-up, which is 6 months
Assess the benefits of following the recommendations
Comparison of disease progression between populations with and without NE (Regression / Stability / Progression / Not evaluated)
Measured: From enrollment to the end of follow-up, which is 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2026
- Study start5 Mar 2026
- Primary completion4 Sep 2027 (estimated)
- Study completion4 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Enteral NutritionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Curie
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07571564
- Sponsor's protocol ID
- DATA25024 ADHENUTE
- Acronym
- ADHENUTE
- Status last verified
- Apr 2026
- First submitted
- 30 Apr 2026
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adherence to Enteral Nutrition
- ClinicalTrials.gov ID
- NCT07571564
- Acronym / sponsor ID
- ADHENUTE / DATA25024 ADHENUTE
- Conditions
- Enteral Nutrition
- Keywords
- enteral nutrition, adherence to enteral nutrition, compliance with enteral nutrition guidelines, malnutrition, nutritional supplements, patient education workshops, training for healthcare staff
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Institut CurieUniversity, hospital or other
- Study start
- 5 Mar 2026 (actual)
- Primary completion
- 4 Sep 2027 (estimated)
- Study completion
- 4 Sep 2027 (estimated)
- First posted
- 6 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Malnutrition is a major challenge in cancer nutrition, affecting approximately 40% of cancer patients and having negative consequences on treatment efficacy, quality of life, and prognosis. It must be detected and managed early, based on clinical and laboratory criteria defined by the HAS recommendations.
To address this, several nutritional strategies are available, ranging from fortified oral feeding to artificial nutrition. Enteral nutrition, which is more physiological and carries fewer risks than parenteral nutrition, is recommended as the first-line treatment. Tools such as personalized care plans and guidelines help tailor patient care.
However, enteral nutrition remains underutilized in clinical practice, despite the recommendations. The ADHENUTE study, conducted at the Institut Curie, showed low compliance with recommendations (31%) and a tendency to favor oral nutritional supplements, even in severely malnourished patients. The lack of traceability of decisions makes it difficult to identify barriers, although patient refusal is sometimes mentioned.
To improve this situation, corrective measures have been implemented:
- for patients, through educational workshops to help them better understand and accept enteral nutrition;
- for healthcare providers, through training sessions to address reservations and enhance knowledge.
A third phase of the study aims to evaluate the impact of these actions, with the goal of increasing adherence to recommendations and the use of enteral nutrition.
Detailed description
The primary goal in cancer nutrition is to prevent, limit, and treat malnutrition. On average, 40% of cancer patients are malnourished (with this prevalence rising to as high as 90% depending on the cancer's location and the stage of the disease). Studies have shown that malnutrition reduces the effectiveness of cancer treatments, patients' quality of life, and their prognosis for recovery.
Screening for and management of malnutrition must be initiated early and based on the recommendations of the French National Authority for Health (HAS) in its guidelines titled "Diagnosis of Malnutrition in Children and Adults," updated in November 2020 and November 2021. In adults, the diagnosis of malnutrition (and its severity) is based on phenotypic and etiological criteria, including weight loss, Body Mass Index (BMI), albumin levels, and muscle strength measurements.
Dietary measures and interventions-ranging from optimizing oral intake to the use of Oral Nutritional Supplements (ONS) and Artificial Nutrition (AN)-help combat malnutrition. Enteral nutrition, which utilizes the digestive system, is the more physiological and effective solution, carrying a lower risk of infection. It is the preferred first-line treatment over parenteral nutrition.
Healthcare professionals can use the HAS's Personalized Care Plans (PPS) for oncology, which propose strategies based on treatment, age, and tumor location, as well as the phase of treatment (curative, initial palliative, advanced, or terminal). The nutritional care decision tree, which establishes a management strategy based on the patient's nutritional status and the severity of malnutrition-and is not specific to oncology-is a validated tool.
Despite the recommendations, the use of enteral nutrition remains insufficient. Indeed, and more broadly, this issue of non-compliance with recommendations for the implementation of enteral nutrition is commonly observed. This is confirmed by the study conducted by Defteros et al., which demonstrated that adhering to ESPEN (European Society for Clinical Nutrition and Metabolism) recommendations in clinical practice is difficult.
At the Institut Curie, until now, there has been little data on the extent to which recommendations for initiating enteral nutrition are followed.
We designed the ADHENUTE study (ADHEsion to Enteral Nutrition) to assess adherence to an enteral nutrition program in medical oncology and compliance with recommendations for implementing this nutritional support, both before and after corrective measures were implemented.
The study is designed in three phases:
> Phase 1: Verification of the hypothesis that enteral nutrition is under-used compared to recommendations, through a retrospective analysis of 200 medical records, and identification of barriers to the implementation of this nutritional support.
This phase was completed and highlighted in an article submitted to the *Bulletin du cancer* in March 2025, titled "Underutilization of enteral nutrition in medical oncology compared to recommendations." This initial phase revealed a compliance rate of 31% with the recommendations for enteral nutrition [95% CI: 20-42]. It also provided insight into which nutritional products were most frequently prescribed. A comparison between the recommended theoretical nutritional management and the management actually implemented in practice reveals a shift away from "enteral nutrition" toward "oral nutritional supplements." Furthermore, among the 189 usable records, 45% of patients were severely malnourished. Patients who received enteral nutrition generally had a poorer nutritional status than the overall study population: 21 out of 22 patients were malnourished (15 severely). However, the more severe the malnutrition, the more resistant it becomes to treatment, rendering dietary measures ineffective [10] and increasing the risk of complications during their implementation (notably an increased risk of inappropriate refeeding syndrome).
In their 2015 article [11], Coti-Bertrand et al. recommend tracking the indication for enteral nutrition as part of their criteria for evaluating and improving practices: "The indication for enteral nutrition is specified in the medical record." In the Adhénute study, documentation did not allow for the identification of the reason for non-compliance with enteral nutrition recommendations in each case. Among the records analyzed, the patient's refusal of enteral nutrition was mentioned in 5 records. For the 50 cases where enteral nutrition was not initiated despite recommendations to do so, this lack of traceability makes it impossible to determine why enteral nutrition was not provided.
- Step 2: Implementation of corrective measures for patients requiring enteral nutrition through an educational presentation of the project, and for healthcare providers and prescribing physicians through training sessions.
The proposal for corrective measures constitutes the second phase of the Adhénute project. These measures were implemented exclusively at the Saint Cloud site. The Paris site benefited from standard practices for improving clinical care.
They targeted two groups:
> Patients for whom enteral nutrition is indicated: The full report on best practices for dietary management in oncology regarding enteral nutrition [12] states that it is recommended to obtain the patient's consent through informed consent.
As part of Adhénute's corrective measures, enteral nutrition programs were presented to patients through educational initiatives such as Patient Therapeutic Education (PTE) workshops, with the aim of improving their understanding of this approach, reducing their level of apprehension, and increasing adherence to this nutritional method. This workshop, titled "I'm Committed to Enteral Nutrition," was designed for individual sessions or to include a caregiver and was offered to patients requiring enteral nutrition-whether in outpatient care or hospitalized-as soon as the need was identified (often on the same day, making it difficult to formalize the workshop into a full-fledged PTE program with a comprehensive pathway including BEPs). It includes 6 tools that can be adapted to the patient (material and nasogastric tube cards / keyword cards / food intake pie chart / choice method cards / arrows to associate with adverse effects / question-and-answer bubbles). The "emotions wheel" is used at the beginning and end of the workshop. An informational brochure is provided at the end of the workshop.
> Healthcare providers (doctors, nurses, nursing assistants). Training sessions were offered to medical and nursing staff.
The results of the first phase of Adhénute were presented to prescribing physicians, along with a review of the recommendations for implementing enteral nutrition during medical staff meetings in the target departments.
A training session titled "Overcoming Reluctance Toward Enteral Nutrition" was offered to medical and nursing teams in the target departments. Designed as a participatory and interactive ETP workshop, this training helped identify common barriers conveyed to patients by healthcare staff, enhance knowledge about this approach, and clarify the expected benefits for the patient.
This step has been completed
> Step 3: Evaluation of the impact of the improvement measures implemented in Step 2 To this end, a prospective analysis of patient records from those hospitalized in a medical oncology unit following the implementation of improvement measures will be conducted at the Saint-Cloud site. We expect to see an increase in the rate of compliance with recommendations as a result of these improvement measures.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- We propose to conduct a prospective, single-center cohort study involving 80 patients. Patients will be enrolled at the Institut Curie in Saint Cloud over a 12-month period and followed for 6 months. Patients must be adults and hospitalized in a medical oncology ward.
Key inclusion criteria (4 listed)
- Patients hospitalized (including those in the day hospital) in a medical oncology unit;
- Adults;
- Men or women;
- Patients for whom enteral nutrition is indicated according to SFNCM recommendations;
Key exclusion criteria (7 listed)
- Minors (under 18 years of age)
- Patients receiving end-of-life palliative care
- Individuals deprived of their liberty or under legal guardianship (including conservatorship);
- Adults under judicial protection;
- Inability to participate in the study for geographical, social, or psychological reasons.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assess compliance with recommendations for the implementation of enteral nutrition following the improvement measures implemented in Phase 2.
Time frame: From enrollment to the end of follow-up, which is 6 months
Percentage of patients for whom the recommendations are followed. Compliance with the recommendations will be assessed by comparing the recommended nutritional interventions with those actually implemented.
10 secondary outcomes
Assess the traceability of the reasons for not following a recommendation to initiate enteral nutrition in the patient's medical record
Time frame: From enrollment to the end of follow-up, which is 6 months
Assess the role of the dietetics department in screening for malnutrition and in the implementation of enteral nutrition
Time frame: From enrollment to the end of follow-up, which is 6 months
Assess the delay in initiating enteral nutrition
Time frame: Since the onset of the disease at the start of enteral nutrition
Evaluate the implementation of recommendations based on tumor location
Time frame: From enrollment to the end of follow-up, which is 6 months
Identify other nutritional support methods used as alternatives to enteral nutrition.
Time frame: From enrollment to the end of follow-up, which is 6 months
Assess the time required for the patient to tolerate enteral nutrition
Time frame: From enrollment to the end of follow-up, which is 6 months
Assess the duration of compliance
Time frame: From enrollment to the end of follow-up, which is 6 months
Describe the reasons for discontinuing enteral nutrition
Time frame: From enrollment to the end of follow-up, which is 6 months
Assessing the resolution of malnutrition through the implementation of recommendations
Time frame: From enrollment to the end of follow-up, which is 6 months
Assess the benefits of following the recommendations
Time frame: From enrollment to the end of follow-up, which is 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
Related trials for Enteral Nutrition
Not yet recruiting
Short-Term Enteral Nutrition for Infants With Bronchiolitis in Pediatric Emergency Departments
Bronchiolitis, Clinical Phenotype
RecruitingPhase 1/2
High-energy Human Milk Diets in the First Two Weeks After Birth to Reduce BPD in Extremely Preterm Infants
Extreme Prematurity, Enteral Nutrition
RecruitingObservational study
Gut Microbiota Changes in Children Receiving Exclusive Enteral Nutrition With Compleat® Paediatric
Feeding and Eating Disorders of Childhood, Enteral Nutrition Dependence
Not yet recruitingObservational study
Comparison of Sedated and Unsedated PEG in Elderly ASA IV Patients
Percutaneous Endoscopic Gastrostomy, Enteral Nutrition Feeding
RecruitingObservational study
Association of Biomarkers and Gastric Antral Motility Index With Feeding Intolerance in Critically Ill Patients
Critically Ill Patients Who Are Not Allowed to Eat Orally But Can Initiate Enteral Nutrition Within 48 Hours of ICU
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Enteral Nutrition, run by Institut Curie at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Betty PEIGNELIN (+33 1 47 11 15 24, betty.peignelin@curie.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess compliance with recommendations for the implementation of enteral nutrition following the improvement measures implemented in Phase 2. (time frame: From enrollment to the end of follow-up, which is 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026; AzTrials last refreshed its copy on 2 Nov 2026.